The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer.
 
David James VanderWeele
Consulting or Advisory Role - Clovis Oncology; Exelixis
Research Funding - AstraZeneca (Inst); Department of Defense-Prostate Cancer Research Program; Fortis (Inst); Prostate Cancer Foundation
 
Masha Kocherginsky
Patents, Royalties, Other Intellectual Property - Royalties - co-inventor on Patent 9149485, "Methods and compositions related to glucocorticoid receptor antagonists and breast cancer".
 
Sabah Munir
No Relationships to Disclose
 
Brenda K. Martone
No Relationships to Disclose
 
Alicia K. Morgans
Honoraria - Advanced Accelerator Applications; Astellas Pharma; Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Clovis Oncology; Exelixis; Genentech; Janssen; Janssen; Janssen Oncology; Merck; Myovant Sciences; Pfizer; Sanofi
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Exelixis; Janssen; Lantheus Medical Imaging; Merck; Myovant Sciences; Myovant Sciences; Myriad Genetics; Novartis; Sanofi
Research Funding - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Dendreon; Genentech; Myovant Sciences; Sanofi; Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Sanofi
 
Walter Michael Stadler
Consulting or Advisory Role - AstraZeneca; Bayer; CVS Caremark; Eisai; Merck; Pfizer; Sotio; Treadwell Therapeutics; Treadwell Therapeutics; Treadwell Therapeutics
Research Funding - Abbvie (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Johnson & Johnson (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Seagen (I); Tesaro (Inst); X4 Pharma (Inst)
Expert Testimony - Teva; Teva
Other Relationship - American Cancer Society; UpToDate
 
Sarki Abdulkadir
No Relationships to Disclose
 
Maha H. A. Hussain
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; Genentech; Merck; MLI PeerView; OncLive; PER; Phillips Gilmore Oncology; projects in Knowledge; Research to Practice; Research to Practice; Research to Practice; Sanofi; UroToday; UroToday
Consulting or Advisory Role - AstraZeneca; Bayer; BMS; Daiichi Sankyo Company; Genentech; Janssen; Merck; Novartis; Pfizer; Pfizer
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Genentech; Genentech/Roche; Pfizer